Form 6-K GLAXOSMITHKLINE PLC For: Jan 17
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 16 January
2017
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline plc
(the ‘Company')
Transaction
notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|||
a)
|
Name
|
Sir
Andrew Witty
|
||
b)
|
Position/status
|
Chief
Executive Officer
|
||
c)
|
Initial
notification/
amendment
|
Initial
notification
|
||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|||
a)
|
Name
|
GlaxoSmithKline
plc
|
||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|||
a)
|
Description
of
the
financial
instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
||
b)
|
Nature
of
the
transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Performance Share
Plan.
|
||
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
230.984
|
|||
£15.66
|
4.229
|
|||
£15.66
|
1414.139
|
|||
£15.66
|
4242.446
|
|||
£15.66
|
5799.902
|
|||
£15.66
|
6281.971
|
|||
£15.66
|
617.137
|
|||
d)
|
Aggregated
information
Aggregated
volume
Price
|
18,590.808
£15.66
|
||
e)
|
Date
of
the
transaction
|
2017-01-12
|
||
f)
|
Place
of
the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|||
a)
|
Name
|
Ms E
Walmsley
|
||
b)
|
Position/status
|
CEO
Designate
|
||
c)
|
Initial
notification/
amendment
|
Initial
notification
|
||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|||
a)
|
Name
|
GlaxoSmithKline
plc
|
||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|||
a)
|
Description
of
the
financial
instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
||
b)
|
Nature
of
the
transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Performance Share
Plan.
|
||
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
1470.538
|
|||
£15.66
|
1507.800
|
|||
£15.66
|
781.531
|
|||
£15.66
|
2574.033
|
|||
d)
|
Aggregated
information
A
ggregated
volume
Price
|
6,333.902
£15.66
|
||
e)
|
Date
of
the
transaction
|
2017-01-12
|
||
f)
|
Place
of
the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|||
a)
|
Name
|
Mr S
Dingemans
|
||
b)
|
Position/status
|
Chief
Financial Officer
|
||
c)
|
Initial
notification/
amendment
|
Initial
notification
|
||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|||
a)
|
Name
|
GlaxoSmithKline
plc
|
||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|||
a)
|
Description
of
the
financial
instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
||
b)
|
Nature
of
the
transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Performance Share
Plan.
|
||
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
2489.181
|
|||
£15.66
|
2552.244
|
|||
£15.66
|
2764.183
|
|||
d)
|
Aggregated
information
Aggregated
volume
Price
|
7,805.608
£15.66
|
||
e)
|
Date
of
the
transaction
|
2017-01-12
|
||
f)
|
Place
of
the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|||
a)
|
Name
|
Mr R G
Connor
|
||
b)
|
Position/status
|
President,
Global Manufacturing & Supply
|
||
c)
|
Initial
notification/
amendment
|
Initial
notification
|
||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|||
a)
|
Name
|
GlaxoSmithKline
plc
|
||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|||
a)
|
Description
of
the
financial
instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
||
b)
|
Nature
of
the
transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Performance Share
Plan.
|
||
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
1144.520
|
|||
£15.66
|
1173.521
|
|||
£15.66
|
1503.083
|
|||
d)
|
Aggregated
information
Aggregated
volume
Price
|
3,821.124
£15.66
|
||
e)
|
Date
of
the
transaction
|
2017-01-12
|
||
f)
|
Place
of
the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|||
a)
|
Name
|
Mr L
Debruyne
|
||
b)
|
Position/status
|
President,
Global Vaccines GSK
|
||
c)
|
Initial
notification/
amendment
|
Initial
notification
|
||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|||
a)
|
Name
|
GlaxoSmithKline
plc
|
||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|||
a)
|
Description
of
the
financial
instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
||
b)
|
Nature
of
the
transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Performance Share
Plan.
|
||
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
327.328
|
|||
£15.66
|
300.181
|
|||
£15.66
|
378.346
|
|||
d)
|
Aggregated
information
Aggregated
volume
Price
|
1,005.855
£15.66
|
||
e)
|
Date
of
the
transaction
|
2017-01-12
|
||
f)
|
Place
of
the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|||
a)
|
Name
|
Mr N
Hirons
|
||
b)
|
Position/status
|
SVP,
Global Ethics & Compliance
|
||
c)
|
Initial
notification/
amendment
|
Initial
notification
|
||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|||
a)
|
Name
|
GlaxoSmithKline
plc
|
||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|||
a)
|
Description
of
the
financial
instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
||
b)
|
Nature
of
the
transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Performance Share
Plan.
|
||
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
568.982
|
|||
£15.66
|
620.023
|
|||
d)
|
Aggregated
information
Aggregated
volume
Price
|
1,189.005
£15.66
|
||
e)
|
Date
of
the
transaction
|
2017-01-12
|
||
f)
|
Place
of
the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|||
a)
|
Name
|
Mr S A
Hussain
|
||
b)
|
Position/status
|
President,
Global Pharmaceuticals
|
||
c)
|
Initial
notification/
amendment
|
Initial
notification
|
||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|||
a)
|
Name
|
GlaxoSmithKline
plc
|
||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|||
a)
|
Description
of
the
financial
instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
||
b)
|
Nature
of
the
transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Performance Share
Plan.
|
||
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
2310.737
|
|||
£15.66
|
2667.111
|
|||
£15.66
|
3006.180
|
|||
d)
|
Aggregated
information
Aggregated
volume
Price
|
7,984.028
£15.66
|
||
e)
|
Date
of
the
transaction
|
2017-01-12
|
||
f)
|
Place
of
the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|||
a)
|
Name
|
Mr D S
Redfern
|
||
b)
|
Position/status
|
Chief
Strategy Officer
|
||
c)
|
Initial
notification/
amendment
|
Initial
notification
|
||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|||
a)
|
Name
|
GlaxoSmithKline
plc
|
||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|||
a)
|
Description
of
the
financial
instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
||
b)
|
Nature
of
the
transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Performance Share
Plan.
|
||
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
821.621
|
|||
£15.66
|
933.481
|
|||
£15.66
|
1089.729
|
|||
d)
|
Aggregated
information
Aggregated
volume
Price
|
2,844.831
£15.66
|
||
e)
|
Date
of
the
transaction
|
2017-01-12
|
||
f)
|
Place
of
the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|||
a)
|
Name
|
Ms C
Thomas
|
||
b)
|
Position/status
|
SVP,
HR
|
||
c)
|
Initial
notification/
amendment
|
Initial
notification
|
||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|||
a)
|
Name
|
GlaxoSmithKline
plc
|
||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|||
a)
|
Description
of
the
financial
instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
||
b)
|
Nature
of
the
transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Performance Share
Plan.
|
||
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
1172.271
|
|||
£15.66
|
1244.646
|
|||
£15.66
|
1371.559
|
|||
d)
|
Aggregated
information
A
ggregated
volume
Price
|
3,788.476
£15.66
|
||
e)
|
Date
of
the
transaction
|
2017-01-12
|
||
f)
|
Place
of
the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|||
a)
|
Name
|
Mr P C
Thomson
|
||
b)
|
Position/status
|
SVP,
Communications & Government Affairs
|
||
c)
|
Initial
notification/
amendment
|
Initial
notification
|
||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|||
a)
|
Name
|
GlaxoSmithKline
plc
|
||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|||
a)
|
Description
of
the
financial
instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
||
b)
|
Nature
of
the
transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Performance Share
Plan.
|
||
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
559.082
|
|||
£15.66
|
720.120
|
|||
£15.66
|
789.120
|
|||
d)
|
Aggregated
information
Aggregated
volume
Price
|
2,068.322
£15.66
|
||
e)
|
Date
of
the
transaction
|
2017-01-12
|
||
f)
|
Place
of
the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|||
a)
|
Name
|
Dr P J
T Vallance
|
||
b)
|
Position/status
|
President,
R&D
|
||
c)
|
Initial
notification/
amendment
|
Initial
notification
|
||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|||
a)
|
Name
|
GlaxoSmithKline
plc
|
||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|||
a)
|
Description
of
the
financial
instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
||
b)
|
Nature
of
the
transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Performance Share
Plan.
|
||
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
2524.897
|
|||
£15.66
|
2588.867
|
|||
£15.66
|
3194.057
|
|||
d)
|
Aggregated
information
Aggregated
volume
Price
|
8,307.821
£15.66
|
||
e)
|
Date
of
the
transaction
|
2017-01-12
|
||
f)
|
Place
of
the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|||
a)
|
Name
|
Mrs V A
Whyte
|
||
b)
|
Position/status
|
Company
Secretary
|
||
c)
|
Initial
notification/
amendment
|
Initial
notification
|
||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|||
a)
|
Name
|
GlaxoSmithKline
plc
|
||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|||
a)
|
Description
of
the
financial
instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
||
b)
|
Nature
of
the
transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Performance Share
Plan.
|
||
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
168.102
|
|||
£15.66
|
159.405
|
|||
£15.66
|
150.648
|
|||
d)
|
Aggregated
information
Aggregated
volume
Price
|
478.155
£15.66
|
||
e)
|
Date
of
the
transaction
|
2017-01-12
|
||
f)
|
Place
of
the
transaction
|
n/a
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: January
16, 2017
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intuitive Announces Board of Directors Elections and Retirements
- Bombardier Announces the Election of its Board of Directors
- Victory Sells Tahlo Lake Property in British Columbia
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!